Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan

Clinical trial NCT00516438 · COMPLETED

Trial details

NCT number: NCT00516438
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Malignant Solid Tumors

Start date: 2007-07-01
Primary completion: 2009-03-01
Enrollment: 48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.